MG Stover Unlocks Next Chapter of Growth with Focus on OTTO
Redefining digital asset reporting with real-time insights, auditable precision, and expert service Denver, CO, April 24, 2025 (GLOBE NEWSWIRE) —…
Toobit Launches Gift, Now Supports Crypto Gifting on Telegram
GEORGE TOWN, Cayman Islands, April 24, 2025 (GLOBE NEWSWIRE) — Award-winning global digital asset trading platform Toobit today announces the…
iSTAR Medical’s MINIject® demonstrates significant sustained 5-year efficacy in treating glaucoma in STAR-GLOBAL trial
For immediate release iSTAR Medical’s MINIject® demonstrates significant sustained 5-year efficacy in treating glaucoma in STAR-GLOBAL trial Five-year safety profile…
Actimed Therapeutics Appoints Shaun Claydon as Chief Financial Officer
London, UK – 24th April 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on…
Bitget Upgrades Liquidity Incentive Program with Top-Tier Maker Rebate for Institutional Traders
VICTORIA, Seychelles, April 24, 2025 (GLOBE NEWSWIRE) — Bitget, the leading cryptocurrency exchange and Web3 company, has announced a major…
Quadient Named a Leader in the SPARK Matrix™: Customer Communication Management Report for 2025
Quadient Named a Leader in the SPARK Matrix™: Customer Communication Management Report for 2025 QKS Group recognizes Quadient for its…
MYT Netherlands Parent B.V. (“Mytheresa”) and Richemont announce the successful completion of Mytheresa’s acquisition of YOOX NET-A-PORTER (“YNAP”)
MYT Netherlands Parent B.V. (“Mytheresa”) and Richemont announce the successful completion of Mytheresa’s acquisition of YOOX NET-A-PORTER (“YNAP”) 24 April…
JZMOR Breaks New Ground in Technological Innovation: High-Performance Matching Engine Empowers Global Traders
GREENWOOD VILLAGE, Colo., April 24, 2025 (GLOBE NEWSWIRE) — Recently, JZMOR Exchange announced the official launch of its next-generation high-performance…
Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients
Primary endpoint met, no drug-related serious adverse events Positive hematoma and edema volume evolution Recruitment stopped early due to positive…
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
Elafibranor showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC, a rare…
Eramet: 2.7bn€ in economic contribution and 260,000 beneficiaries of social initiatives in the countries where it operates by 2024
PRESS RELEASE Paris, April 24, 2025, 8:00 am Eramet: 2.7bn€ in economic contribution and 260,000 beneficiaries of social initiatives in the…
Pharming Group to report first quarter 2025 financial results on May 8
Leiden, the Netherlands, April 24, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited)…
↑